No Zafgen IPO Yet; It Plans a $40M Crossover Round
This article was originally published in The Pink Sheet Daily
The private obesity company will do a mezzanine venture financing that brings in at least one public-oriented investor before it heads, presumably, toward an IPO. That round is slated to close in a month or so. Around the same time, Zafgen will present final Phase II data for its beloranib.